These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255 [TBL] [Abstract][Full Text] [Related]
6. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Sandhu SK; Yap TA; de Bono JS Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194 [TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897 [TBL] [Abstract][Full Text] [Related]
8. PARP and PARG inhibitors--new therapeutic targets in cancer treatment. Fauzee NJ; Pan J; Wang YL Pathol Oncol Res; 2010 Dec; 16(4):469-78. PubMed ID: 20383759 [TBL] [Abstract][Full Text] [Related]
9. Development of PARP inhibitors in oncology. Rodon J; Iniesta MD; Papadopoulos K Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880 [TBL] [Abstract][Full Text] [Related]
10. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor. Wang B; Qian H; Yiu SM; Sun J; Zhu G Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480 [TBL] [Abstract][Full Text] [Related]
11. [PARP inhibitors: significant progress in cancer therapy]. Dantzer F; Noel G; Schreiber V Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis. Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274 [TBL] [Abstract][Full Text] [Related]
15. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Pommier Y; O'Connor MJ; de Bono J Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957 [TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of poly(ADP-ribose) polymerase in cancer. Plummer ER Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340 [TBL] [Abstract][Full Text] [Related]
18. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Sakamoto-Hojo ET; Balajee AS Anticancer Agents Med Chem; 2008 May; 8(4):402-16. PubMed ID: 18473725 [TBL] [Abstract][Full Text] [Related]
19. Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Menear KA; Adcock C; Alonso FC; Blackburn K; Copsey L; Drzewiecki J; Fundo A; Le Gall A; Gomez S; Javaid H; Lence CF; Martin NM; Mydlowski C; Smith GC Bioorg Med Chem Lett; 2008 Jul; 18(14):3942-5. PubMed ID: 18579376 [TBL] [Abstract][Full Text] [Related]
20. [Construction of pharmacophore model of PARP-1 inhibitor]. Zhang WT; Yan H; Jiang FC Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]